AKTX vs ALDX

Akari Therapeutics Plc vs Aldeyra Therapeutics, Inc. — Valuation Comparison 2026

AKTX

Biotechnology
Akari Therapeutics Plc
Quality
1.7
out of 10
Value Trap
12
SAFE
Price
$22.05
Last close
Models
7/13
Active
VS

ALDX

Biotechnology
Aldeyra Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
30
LOW
Price
$1.75
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType AKTX Fair ValueAKTX Upside ALDX Fair ValueALDX Upside
Bayesian DCF Intrinsic $5.78 -73.8% $0.96 -45.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.26 -35.3% $0.07 -95.3%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $23.73 +307.8% $1.82 +3.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AKTX vs ALDX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AKTX vs ALDX — Which Stock Is More Undervalued?

ALDX scores higher with a 4.5/10 quality rating vs AKTX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Akari Therapeutics Plc (AKTX) and Aldeyra Therapeutics, Inc. (ALDX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AKTX currently trades at $22.05 with a QOC of 1.7/10, while ALDX trades at $1.75 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).